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Abstracts / Urological Science 27 (2016) S36eS52S50survival (PFS) deﬁned as no biochemical relapse (two consecutive rises in
prostate-speciﬁc antigen [PSA] with a velocity>0.4 ng/ml per year or PSA
>1.5 ng/ml) and no additional treatment. Adverse events in terms of
genitourinary and gastrointestinal toxicity were reported.
Results: Themean follow-up of the 121 patients was 32.7months and total
11 patients underwent salvage radiotherapy. Six patients received SRT and
hormone therapy. Five patients received SRT alone. 6-month progression-
free survival was observed in total 6 patients receiving SRT and hormone
therapy achieved. However, biochemical relapse was documented in two
patients, 9.47 and 12.20 months after salvage treatment completed,
respectively. Among 5 patients receiving SRT alone, two patients
encountered treatment failure. There is 1 patient who had histologically
proven local relapse. 6-month progression-free survival was observed in
the other 2 patients. Salvage radiotherapy was discontinued on 1 patient,
who developed grade 4 ileus after 2400 cGy of radiation. There was also 2
patients getting grade 3 gastrointestinal toxicity, bloody stool and anal
ulcer with bleeding, respectively. Otherwise, gastrointestinal toxicity was
low. All genitourinary toxicity are grade 1e2. Three patients had no
genitourinary symptom.
Conclusion: In this preliminary study, combined radiotherapy and hor-
mone therapy seemed provided satisfactory oncologic control after for
salvage treatment after primary HIFU failure. Though genitourinary and
gastrointestinal toxicity were usually low, Grade 3e4 toxicity was still
noted. These results warrant further and longer investigation.
MP6-2.
PSA FLARE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
PATIENTS TREATED WITH ABIRATERONE OR DOCETAXEL
Hui-Ying Liu, Yuan-Chi Shen, Cheng-Jen Yu, Po-Hui Chiang. Division of
Urology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University
College of Medicine, Taiwan
Purpose: The aim of this study was to assess PSA ﬂare up phenomenon in
the treatment of metastatic castration-resistant prostate cancer (mCRPC)
patients with abiraterone or docetaxel and to correlate with clinical
outcome.
Materials and Methods: We retrospectively evaluated 92 patients with
metastatic castrate-resistant prostate cancer (CRPC) either treated with
abiraterone or docetaxel at our institution. Baseline serum PSA levels were
checked before treatment and followed bymonitoring every 4weeks in the
group of abiraterone and every cycle in the groupof docetaxel. The PSAﬂare
phenomenonwas evaluated. Clinical outcomes were evaluated to compare
survival between groups of patients according to variations of PSA level.
Results: Of 92 patients, 73 patients received docetaxel therapy and 19
patients treated with abiraterone. They were classiﬁed into four groups:
stabilization (PSA decline <50%), PSA progression, primary responder (PSA
decline S 50%), and ﬂare-up phenomenon. Six patients (8.2%) got doce-
taxel therapy and two patients (10.5%) got abiraterone therapy were
identiﬁed with PSA ﬂare phenomenon. We compared the overall survival
between group of PSA decline> 50% with the ﬂare-up group. There was no
statistical difference in survival between two groups.
Conclusion: There is a considerable portion of mCRPC patients experience
PSA ﬂare under either abiraterone or docetaxel therapy. There was no
statistical difference in survival between PSA responder and PSA ﬂare-up
phenomenon group. Patients should be informed of this effect to avoid
early, and thereby inadequate, discontinuation of treatment.
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SYSTEMIC REVIEW OF MALIGNANCY AFTER ILEOCYSTOPLASTY
Chi-Wen Lo, Shang Jen Chang, Chang-Hsin Hsieh, Shei-Dei Yang. Divisions
of Urology, Department of Surgery, Taipei Tzu Chi Hospital, New Taipei,
Taiwan
Purpose: The incidence of post-ileocystoplasty malignancy is low and
most published reports were case reports and only few single-cancer
retrospective cohort study presented. Therefore, we systemically reviewed
the published reports to pool the results for analysis to more clearly
illustrate the characteristics and prognosis of malignancy associated with
ileocystoplasty.Materials and Methods: We did a systemic search of the PubMED® and
CiNii for all cases with the following keywords: cystoplasty, enter-
ocystoplasy, ileocystoplasty, ileum, urinary diversion, and malignancy or
bladder cancer. The additional records on this topic were identiﬁed from
references cited in the selected articles and previous review articles on this
topic. Two of the authors (CWL and SJC) independently did the literature
search and data extraction. The parameters retrieved from the reports
included baseline patient characteristics, latency period, indications for
surgery, presenting symptoms and signs, histological type, locus of tumor,
follow-up period and survival which were analyzed with commercial
software (Medcalc®, version 9.3, USA).
Results: There were 41 articles selected and analyzed prudently with 56
cases included in the review. The reported incidence ranged from 0.9% to
5.5% in patients underwent ileocystoplasty. The average age was
53.0 ± 11.8 years old. Most malignancy occurred 15 years after ileocysto-
plasty (47/56, 83.9%) and the most commonly presenting symptoms were
gross hematuria (60.0%). The locations of malignancy were mainly located
at the ileobladder junction. Adenocarcinoma is most commonly observed
histology among all cases (39/56) while urothelial carcinoma predomi-
nated in cases with neurogenic bladder (5/10). 17 of 45 patients (37.8%)
presented with advanced disease and poor prognosis (median survival
time was 6.0 months).
Conclusion: The systemic review revealed low incidence of post-ileocys-
toplasty malignancy with majorly poor prognosis. Yearly cystoscopy sur-
veillance may not be indicated in case within 15 years post-operatively
except symptomatic patients.
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A PRELIMINARY REPORT: THE APPLICATION OF HO-YAG LASER IN
TURBT WITH ENBLOC METHOD
Chi-Wen Lo, Shang Jen Chang, Chang-Hsin Hsieh, Shei-Dei Yang. Divisions
of Urology, Department of Surgery, Taipei Tzu Chi Hospital, New Taipei,
Taiwan
Purpose: The traditional TURBT surgery still have several drawbacks
include fragmentation, cauterization effect and easily disorientation. In
here, we reviewed our patients receiving laser en bloc TURBT to compared
the traditional TURBT with the feasibility, oncology outcome and
complication rate.
Materials and Methods: We reviews patients newly diagnosed and
received TURBT surgery in our hospital from 2011 to 2014. Patients who
were loss of following up/ under unresectable status were all excluded. The
age, body weight, height and sex were all recorded. The number, grade and
stage of tumor were all recorded. Also, the complication during the
operation were also reviewed based on medical record.
Results: From2011 to 2014, therewere 10 patients received laser TURBTand
52 patients received traditional TURBTsurgery. The detrusormuscle harvest
rate was 91.6% in Laser TURBT group and 77.4% in traditional TURBT group
(p¼0.44). Themean following timewas 25.5months (Median 23.1months).
The total recurrence ratewas 11.9% (2/9) in Laser TURBTgroupand22.4% (13/
58) in cTa/ cT1/ cT2 group. In comparison the recurrence rate inT1/ Ta group,
the detrusormuscle (+) group has lower recurrence rate in both laser TURBT
group (25.0%) and traditional TURBTgroup (24.2%) than the detrusormuscle
() group (40%). All the procedures have no complication recorded.
Conclusion: The application of laser with En-bloc method in TURBT is a
good alternative which could increase the diagnosis accuracy and lower
the recurrence rate.
MP6-5.
COMPARISONS OF FUNCTIONAL OUTCOMES AND QUALITY OF LIFE
AFTER NEOBLADDER RECONSTRUCTION: PROSTATE-SPARING
CYSTECTOMY VERSUS RADICAL CYSTOPROSTATECTOMY
Chiang Po Hui, Chen Po Yen. Kaohsiung Chang Gung Medical Center,
Department of Urology, Taiwan
Purpose: To compare functional outcomes on erectile function, conti-
nence, voiding functions, and life quality among bladder patients under-
went neobladder reconstruction after prostate-sparing cystectomy (PSC)
and conventional radical cystoprostatectomy (CRC).
